SCHEMBL1746770

SCHEMBL1746770

Cc1[c]cc2c(c1)CCC(=O)N2C

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 8/20 0.40
CYP11B1 P15538 7/20 0.40
CYP19A1 P11511 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP17A1 P05093 1/20 0.40
BRD4 O60885 2/20 0.39
CREBBP Q92793 1/20 0.39
TRIM24 O15164 3/20 0.39
SRD5A1 P18405 5/20 0.38
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
CYP3A4 P08684 2/20 0.36
SRD5A2 P31213 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744658 0.86 SRD5A1 (0.38) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL1098492 0.81 CYP11B2 (0.40) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL1744656 0.79 CYP11B2 (0.39) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL1746069 0.79 ATAD2 (0.38) BRD4
SCHEMBL423546 0.74 CYP11B2 (0.44) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL422074 0.71 SRD5A1 (0.58) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL8554100 0.71 SRD5A1 (0.39) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL1450547 0.70 TRIM24 (0.39) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1
SCHEMBL1744239 0.70 CYP11B2 (0.43) CYP11B2CYP11B1PDE3BPDE3A
SCHEMBL1023151 0.69 HSD17B10 (0.49) CYP11B2CYP11B1CYP19A1CYP1A2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US claimed
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 US disclosed
EP-2385939-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2011-11-16 EP disclosed
US-8041551-B1 Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components THE MATHWORKS, INC. (US) 2011-10-18 US disclosed
WO-2010072597-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS P2RY1, P2RX3, P2RX1 CYP11B2 2591/4885CYP11B1 2424/4885CYP19A1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.